Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Frank‐Thorsten Hafner"'
Autor:
Dieter Zopf, Iduna Fichtner, Ajay Bhargava, Wolfram Steinke, Karl‐Heinz Thierauch, Konstanze Diefenbach, Scott Wilhelm, Frank‐Thorsten Hafner, Michael Gerisch
Publikováno v:
Cancer Medicine, Vol 5, Iss 11, Pp 3176-3185 (2016)
Abstract Regorafenib is an orally administered inhibitor of protein kinases involved in tumor angiogenesis, oncogenesis, and maintenance of the tumor microenvironment. Phase III studies showed that regorafenib has efficacy in patients with advanced g
Externí odkaz:
https://doaj.org/article/16c86fc82aff40a3b594ce21968b89fc
Autor:
Konstanze Diefenbach, Michael Gerisch, Dieter Lang, Martin Radtke, Frank-Thorsten Hafner, John Lettieri, Adriaan Cleton
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose To evaluate the mass balance, metabolic disposition, and pharmacokinetics of a single dose of regorafenib in healthy volunteers. In addition, in vitro metabolism of regorafenib in human hepatocytes was investigated. Methods Four healthy male
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea118d9d9935d6ba0621d1b197c73418
https://doi.org/10.1007/s00280-017-3480-9
https://doi.org/10.1007/s00280-017-3480-9
Autor:
Barbara Schuett, Frank S Zollmann, Andreas Kaiser, Beate Rohde, Joachim Hoechel, Frank-Thorsten Hafner, Marcus-Hillert Schultze-Mosgau
Publikováno v:
Int. Journal of Clinical Pharmacology and Therapeutics. 55:16-24
Objectives Vilaprisan is a novel, potent, and highly selective progesterone receptor modulator, which might offer a promising option for the treatment of uterine fibroids. Methods and materials In this randomized, placebo-controlled, parallel-group p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94fa43e454f8748c9f2e5ced4cab418b
https://doi.org/10.5414/cp202756
https://doi.org/10.5414/cp202756
Autor:
Frank-Thorsten Hafner, Carsten Schmeck, Roland Heinig, Alexandros Vakalopoulos, Hilmar Bischoff, Klemens Lustig, Klaus Buehner, Stefan Willmann, Volkhart Min-Jian Li, Olaf Weber
Publikováno v:
British Journal of Clinical Pharmacology. 73:219-231
The purpose of this work was to support the prediction of a potentially effective dose for the CETP-inhibitor, BAY 60-5521, in humans.A combination of allometric scaling of the pharmacokinetics of the CETP-inhibitor BAY 60-5521 with pharmacodynamic s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0bef16ac0e693cddb037a092a49ba25
https://doi.org/10.1111/j.1365-2125.2011.04064.x
https://doi.org/10.1111/j.1365-2125.2011.04064.x
Autor:
Martin Radtke, Ping He, Sharyn D. Baker, Ming Zhao, Manuel Hidalgo, John Wright, Frank Thorsten Hafner, Wells A. Messersmith, B. Douglas Smith, Michelle A. Rudek
Publikováno v:
Journal of Chromatography B. 846:1-7
A rapid, sensitive and specific method was developed and validated using LC/MS/MS for determination of sorafenib in human plasma. Sample preparation involved a single protein precipitation step by the addition of 0.1 mL of plasma with 0.5 mL acetonit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::109a8376cf1c262680f3f9852e18b88f
https://doi.org/10.1016/j.jchromb.2006.06.005
https://doi.org/10.1016/j.jchromb.2006.06.005
Autor:
David Brückner, Gabriele Wirtz, Alexandros Vakalopoulos, Carsten Schmeck, Frank-Thorsten Hafner, Joachim Telser, Volkhart Min-Jian Li
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 15:3611-3614
Derivatives of the natural product 11-hydroxy-3-[(S)-1-hydroxy-3-methylbutyl]-4-methoxy-9-methyl-5H,7H-dibenzo[b,g][1,5]dioxocin-5-one 1 were studied as novel CETP inhibitors. Compound 2 was identified from HTS as a micromolar inhibitor. The compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92a6c151cf0d0e0a63b80c16027280ca
https://doi.org/10.1016/j.bmcl.2005.05.073
https://doi.org/10.1016/j.bmcl.2005.05.073
Publikováno v:
Bioanalysis. 6(14)
Background: Regorafenib (BAY 73-4506, commercial name Stivarga®) is an oral multikinase inhibitor developed by Bayer Pharma AG (Germany) that targets angiogenic, stromal and oncogenic receptor tyrosine kinases. An isotope dilution liquid chromatogra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::892a7bc1d545f838a822c3c03d6d3779
https://pubmed.ncbi.nlm.nih.gov/25158964
https://pubmed.ncbi.nlm.nih.gov/25158964
Autor:
Frank-Thorsten Hafner
Publikováno v:
Nachrichten aus Chemie, Technik und Laboratorium. 45:217-217
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::28a1a54ef98f3b06db1a5f82e3478609
https://doi.org/10.1002/nadc.19970450225
https://doi.org/10.1002/nadc.19970450225